Wilms Tumor Nephroblastoma Therapeutics Pipeline Review, H2 2012

							RnR Market Research Offers “Wilms’ Tumor (Nephroblastoma) – Pipeline Review, H2 2012”
Report at US$ 2000 (Single User License). The report got published in Nov 2012 & contains
33 pages.




Wilms’ Tumor (Nephroblastoma) – Pipeline Review, H2 2012

Summary

RnR Market Research, ‘Wilms’ Tumor (Nephroblastoma) – Pipeline Review, H2 2012′, provides an overview
of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for
Wilms’ Tumor (Nephroblastoma), complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for Wilms’ Tumor
(Nephroblastoma). Wilms’ Tumor (Nephroblastoma) – Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from company/university sites and industry-
specific third party sources, put together by Global Markets Direct’s team.

Scope

       A snapshot of the global therapeutic scenario for Wilms’ Tumor (Nephroblastoma).
       A review of the Wilms’ Tumor (Nephroblastoma) products under development by companies and
        universities/research institutes based on information derived from company and industry-specific
        sources.
       Coverage of products based on various stages of development ranging from discovery till
        registration stages.
       A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
       Coverage of the Wilms’ Tumor (Nephroblastoma) pipeline on the basis of route of administration and
        molecule type.
       Key discontinued pipeline projects.
       Latest news and deals relating to the products.

Get your report copy of this report @ http://www.rnrmarketresearch.com/wilms-tumor-
nephroblastoma-pipeline-review-h2-2012-market-report.html

Reasons to buy

       Identify and understand important and diverse types of therapeutics under development for Wilms’
        Tumor (Nephroblastoma).
       Identify emerging players with potentially strong product portfolio and design effective counter-
        strategies to gain competitive advantage.
       Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
       Devise corrective measures for pipeline projects by understanding Wilms’ Tumor (Nephroblastoma)
        pipeline depth and focus of Indication therapeutics.
       Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
        the most attractive projects to enhance and expand business potential and scope.
      Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
       that drove them from pipeline.

Table Of contents

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Wilms' Tumor (Nephroblastoma) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Wilms' Tumor (Nephroblastoma) 7
Wilms' Tumor (Nephroblastoma) Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Wilms' Tumor (Nephroblastoma) Therapeutics - Products under Investigation by Universities/Institutes 14
Wilms' Tumor (Nephroblastoma) - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
vincristine sulfate - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Dactinomycin + Doxorubicin + Vincristine - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Tumor Lysate Pulsed Dendritic Cell Vaccine + Stem Cell Transplantation - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile
24
Product Description 24
Mechanism of Action 24
R&D Progress 25
PS-341 + Vorinostat - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
doxorubicin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RO4929097 + Dexamethasone - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Wilms' Tumor (Nephroblastoma) Therapeutics - Dormant Products 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Number of Products Under Development for Wilms' Tumor (Nephroblastoma), H2 2012 7
Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Assessment by Monotherapy Products, H2 2012 15
Assessment by Combination Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Wilms' Tumor (Nephroblastoma) Therapeutics - Dormant Products 31
List of Figures
Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2012 7
Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 15
Assessment by Combination Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20

For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441

Website: http://www.rnrmarketresearch.com/